Everything below concerns incretin. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-06-13. Numbers and descriptions here follow the published literature rather than marketing material.
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
Trial reports for this compound rely on a small set of repeated measures. Body weight is normally expressed as percent change from baseline at a fixed week, with absolute kilograms given secondarily. Glycemic endpoints include HbA1c, fasting glucose, and, in some protocols, continuous glucose monitoring summaries. Imaging endpoints such as MRI-derived proton density fat fraction quantify liver fat. Standardization matters because a percent change and a categorical responder analysis can tell different stories about the same dataset.
Body composition is assessed with dual-energy X-ray absorptiometry or comparable methods, which separate fat mass from lean mass. Reported losses include both compartments, and the ratio between them is a subject of ongoing analysis rather than a settled result. Waist circumference, blood pressure, and lipid panels are collected as supporting measures. Resting energy expenditure and substrate oxidation are measured in smaller mechanistic studies, where glucagon receptor activity is expected to matter. These substudies are typically short and small, so their findings carry wide uncertainty.
Interpretation depends on study phase and duration. Phase 2 programs are powered for weight and safety signals, not for cardiovascular or renal outcomes, which require event-driven designs. Gastrointestinal events such as nausea, diarrhea, vomiting, and constipation are the most frequently reported adverse effects and tend to cluster around dose escalation. Small increases in heart rate have been described. Because follow-up after treatment discontinuation is limited, questions about weight regain and durability are open rather than answered.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Not a small molecule |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist activity |
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Soluble in water | Also in aqueous buffers |
| Storage | −20 °C or below | Protect from light and moisture |
Retatrutide is an investigational synthetic peptide engineered to activate three distinct hormone receptors within a single molecule. It targets the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor simultaneously. This triagonist design distinguishes it from earlier incretin-based compounds that act on one or two of these pathways. Structural modifications relative to native gut hormones extend its residence time in circulation. The molecule remains under clinical evaluation and is not approved for any indication.
Receptor activation produces downstream effects that differ by tissue. GLP-1 receptor signaling influences appetite regulation and insulin secretion in a glucose-dependent manner. GIP receptor activity contributes to metabolic handling of nutrients and may modulate adipose tissue. Glucagon receptor engagement raises energy expenditure and promotes hepatic lipid turnover, though the balance among these actions in humans is still being characterized. Preclinical models showed reductions in body weight and improved glycemic markers.
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
瑞他鲁肽同时激活GLP-1受体、GIP受体和胰高血糖素受体，这三者均属于B类G蛋白偶联受体。受体激活后主要经cAMP信号通路传递效应。GLP-1成分与食欲抑制和胃排空延缓相关，GIP成分影响脂肪组织与胰岛素分泌，胰高血糖素成分则促进肝糖输出和能量消耗。各受体贡献的相对比例在人体中尚未完全量化。
该分子是经过结构修饰的合成肽，通过脂肪酸侧链与白蛋白结合，从而延长循环时间。皮下给药后，药物逐步释放并分布至组织。降解主要依赖蛋白酶，肾脏清除占次要地位。人体半衰期以天为单位，但准确数值随检测方法和个体差异而变；组织分布与受体占有率仍是开放问题。
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
== History == The use of drugs in sports goes back centuries, about back to the very invention of the concept of sports. In ancient times, when the fittest of a nation were selected as athletes or combatants, they were fed diets and given treatments considered beneficial to help increase muscle. For instance, Scandinavian mythology says Berserkers could drink a mixture called "butotens" to greatly improve their physical power at the risk of insanity, which is thought to have been prepared using the Amanita muscaria mushroom. The ancient Olympics in Greece have been alleged to have had forms of doping. In ancient Rome, where chariot racing had become a huge part of their culture, athletes drank herbal infusions to strengthen them before chariot races. From that moment, people started to introduce their specific diets to improve their performance. Lots of athletes were mainly focusing on achieving superiority and winning the competition by increasing muscle strength capacity and endurance. Charmis, the Spartan winner of the Stade race in the Olympic Games of 668 BC, introduced the special diet of consuming enough dried figs during the training period. A participant in an endurance walking race in Britain, Abraham Wood, said in 1807 that he had used laudanum (which contains opiates) to keep him awake for 24 hours while competing against Robert Barclay Allardyce. By April 1877, walking races had stretched to 800 kilometres (500 mi) and the following year, also at the Agricultural Hall in Islington, London, to 840 kilometres (520 mi). The Illustrated London News chided:
=== Disadvantages === The site of putting the patches for topical drugs may get irritated and have rashes and feel itchy. Hence, some topical drugs including nicotine patches for smoking cessation are advised to change places for each application to avoid continuous irritation of the skin. Also, since the drug needs to penetrate the skin, some drugs may not be able to pass through the skin. Some drugs are then "wasted" and the bioavailability of the drug will decrease.
In Africa, European colonial governments and European Christian missionaries criminalized and stigmatized the cultural practices of tattooing and scarification; consequently, the practices underwent decline, ended, or continued to be performed as acts of resistance. Among the ethnic groups in sub-Saharan Africa that traditionally practice scarification are the Gonja, Dagomba, Frafra, Mamprusi, Nanumba, Bali, Tɔfin, Bobo, Montol, Kofyar, Yoruba, and Tiv people of West Africa, and the Dinka, Nuer, Surma, Shilluk, Toposa, Moru, Bondei, Shambaa, Barabaig, and Maasai people of East Africa.
Sources: en.wikipedia.org
== History == Frederick L. "Freddy" Simon grew up in Colwich, Kansas, near Wichita. He was a World War II veteran, joining the U.S. Army infantry in 1943 and serving in the 1st Cavalry Division. He was awarded the Purple Heart due to combat wounds sustained in the Pacific Theater, as well as a Bronze Star for valor. After the war, Simon worked for the same company in the hospitality industry for 55 years, building connections with many restaurateurs. Freddy lent his name to, and was a business partner in, a Simon family-owned restaurant called Freddy's Frozen Custard & Steakburgers. Founded by his sons Randy and Bill and Bill's friend, restaurateur Scott Redler, the first location opened in Wichita on August 26, 2002. Freddy's quickly gained a loyal customer base, leading to further expansion beginning in 2004. Freddy's menu has remained consistent over the years, offering signature steakburgers, Vienna Beef hot dogs, and fresh frozen custard desserts across all locations. The food was based on "All American" meals that Freddy had served his own family, with the setting of the restaurant based on fast-casual dining of the late 1940s and early 1950s, evoking "a post-war era of optimism, pride, and values focusing on unity and quality family time." On December 17, 2016, Freddy's co-founder Bill Simon died at the age of 61 after a battle with cancer. Freddy Simon died at the age of 95 on October 25, 2020. In March 2021, private equity firm Thompson Street Capital Partner purchased Freddy's Frozen Custard & Steakburgers for an undisclosed amount.
KDEL receptors initiate the mechanism by which proteins are transported from the Golgi to the ER. These proteins were originally from the ER and they escaped into the cis-Golgi. The KDEL signal sequence is recognized by KDEL receptors, which are commonly located in the cis-Golgi, lysosomes, and secretory vesicles. These receptors are recycled during each transport cycle. KDEL receptor binding is dependent on pH, in which the ligand (target protein) binds strongly to the receptor in the cis-Golgi due to the unique low pH (6, in in vitro experiments pH 5 shows strongest binding) characteristic of the biochemical environment of the cis-Golgi network. As the vesicle that contains the KDEL receptor reaches the ER, the receptor is inactive due to the high pH (7.2-7.4) of the ER, resulting in the release of the target protein/ligand. A study conducted by Becker et al. demonstrated through experimentation and simulation that KDEL receptors/cargo clustering at the cell surface is caused by the transport of cargo-synchronized receptors from and to the plasma membrane. The video on the right demonstrates an experiment conducted by Becker et al. demonstrating the dynamics of the KDEL receptor clustering's time dependence with a full experiment from start to finish (60 minutes). Within the paper, the authors note the importance of understanding the mechanism of action of the receptor clustering and dynamic reorganization because of its potential understanding to use for designing targeted therapeutics.
== Pharmacology == GnRH antagonists competitively and reversibly bind to GnRH receptors in the pituitary gland, blocking the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) from the anterior pituitary. In men, the reduction in LH subsequently leads to rapid suppression of testosterone production in the testes; in women it leads to suppression of estradiol and progesterone production from the ovaries. GnRH antagonists are able to abolish gonadal sex hormone production and to suppress sex hormone levels into the castrate range, or by approximately 95%. Unlike the GnRH agonists, which cause an initial stimulation of the hypothalamic–pituitary–gonadal axis (HPG axis) that leads to a surge in testosterone or estrogen levels, GnRH antagonists have an immediate onset of action and rapidly reduce sex hormone levels without an initial surge.
Sources: en.wikipedia.org
=== 1970s to 2011 === Though e-commerce on the dark web started around 2006, illicit goods were among the first items to be transacted using the internet, when in the early 1970s students at Stanford University and Massachusetts Institute of Technology used the ARPANET to coordinate the purchase of cannabis. By the end of the 1980s, newsgroups like alt.drugs would become online centres of drug discussion and information; however, any related deals were arranged entirely off-site directly between individuals. With the development and popularization of the World Wide Web and e-commerce in the 1990s, the tools to discuss or conduct illicit transactions became more widely available. One of the better-known web-based drug forums, The Hive, launched in 1997, serving as an information sharing forum for practical drug synthesis and legal discussion. The Hive was featured in a Dateline NBC special called The "X" Files in 2001, bringing the subject into public discourse. From 2003, the "Research Chemical Mailing List" (RCML) would discuss sourcing "Research Chemicals" from legal and grey sources as an alternative to forums such as alt.drugs.psychedelics. However Operation Web Tryp led to a series of website shut downs and arrests in this area. Since the year 2000, some of the emerging cyber-arms industry operates online, including the Eastern European "Cyber-arms Bazaar", trafficking in the most powerful crimeware and hacking tools. In the 2000s, early cybercrime and carding forums such as ShadowCrew experimented with drug wholesaling on a limited scale.
== E == eIF-2 - eIF-2 kinase - electrochemical potential - electron - electron capture - electron configuration - electron microscopy - electron shell - electron transport chain - electron volt - electronegativity - electrophile - electrophoresis - electrophysiology - element - element symbol - ELISA - ELISPOT - embryo - embryonal development - emulsion - endergonic reaction - endodermis - endomembrane system - endoplasmic reticulum - endothelin receptor - endothelin-1 - energy decomposition cycles - energy level - enhancer - enkephalin - enthalpy - entomology - entropy - env gene product - environmental chemistry - enzyme - epidermal growth factor - epidermal growth factor receptor - epidiorite - epigenetics - epinephrine - equine gonadotropin - erbA gene - erbB gene - erbB-2 gene - erbB-2 receptor - erythropoietin - erythropoietin receptor - essential amino acid - ester - estradiol receptor - estrogen receptor - ethanol - ether - eukaryote - evolution - evolutionary biology - evolutionary developmental biology - evolutionary tree - excretion - exergonic reaction - exon - extracellular matrix protein - eye proteins
=== Narcotic analgesics === Narcotic analgesics tend to be opioids. They bind to opioid receptors which are G protein-coupled receptors distributed in brain, spinal cord, digestive tract, peripheral neurons.
Sources: en.wikipedia.org
Retatrutide is an investigational synthetic peptide that activates three metabolic receptors: GLP-1, GIP, and glucagon. It is being studied for obesity and type 2 diabetes. It has not been approved for clinical use.
Earlier incretin therapies engage one or two receptors. Retatrutide adds glucagon receptor activity, which may raise energy expenditure. Whether this produces larger clinical benefits is still being tested.
It has completed phase 2 trials and moved into later-stage evaluation. No regulator has granted approval. Access outside research settings is not authorized.
A responder analysis counts participants who cross a threshold, such as five or ten percent weight loss. It complements average percent change by showing how widely results are distributed. The two measures can diverge when a subset of participants loses a large amount.